Attached files

                                  EXHIBIT 99.1






8229 Boone Boulevard, Suite 802                          COMPANY CONTACT:
Vienna, VA  22182.  USA                                  Gavin de Windt
Telephone (703) 506-9460                                 CEL-SCI Corporation
www.cel-sci.com                                          (703) 506-9460

             CEL-SCI CORPORATION ANNOUNCES PROPOSED PUBLIC OFFERING
                          OF COMMON STOCK AND WARRANTS

Vienna, VA, October 7, 2013 - CEL-SCI  Corporation (NYSE MKT: CVM), a late-stage
oncology company, today announced that it intends to offer and sell common stock
and warrants,  subject to market and other conditions, in an underwritten public
offering.  The  shares  and  warrants  are being  offered  under  the  Company's
effective shelf registration  statement previously filed with the Securities and
Exchange  Commission  (SEC).  CEL-SCI  intends  to use the net  proceeds  of the
offering  for  general  corporate   purposes,   including  working  capital  and
operational purposes, and including product development.

Chardan  Capital  Markets  is acting as sole  bookrunner  for the  offering  and
Laidlaw & Company (UK) Ltd. is acting as co-manager on the deal.

The  securities  will  be  offered  by  means  of a  prospectus  supplement  and
accompanying prospectus, forming a part of the effective registration statement,
a copy of which may be obtained,  when  available,  at the website of the SEC at
http://www.sec.gov.  Electronic copies of the preliminary prospectus also may be
obtained from Chardan Capital  Markets,  LLC Capital  Markets,  17 State Street,
Suite 1600, New York, NY 10004, at 646-465-9012.

This press release shall not constitute an offer to sell or the  solicitation of
an  offer  to buy  these  securities,  nor  shall  there  be any  sale of  these
securities in any  jurisdiction in which such offer,  solicitation or sale would
be unlawful prior to the registration or qualification under the securities laws
of any such jurisdiction.

About CEL-SCI:

CEL-SCI is  dedicated  to research and  development  directed at  improving  the
treatment  of cancer and other  diseases by  utilizing  the immune  system,  the
body's natural defense  system.  The lead  investigational  therapy is Multikine
(Leukocyte Interleukin,  Injection), currently being studied in a pivotal global
Phase  III  clinical   trial.   CEL-SCI  is  also   investigating   a  different
peptide-based  immunotherapy  (LEAPS-H1N1-DC)  as a possible  treatment for H1N1
hospitalized   patients  and  a  vaccine  (CEL-2000)  for  Rheumatoid  Arthritis
(currently in preclinical  testing)  using its LEAPS  technology  platform.  The
investigational  immunotherapy  LEAPS-H1N1-DC  treatment  involves  non-changing
regions of H1N1  Pandemic  Flu (See Journal of Clinical  Investigation  - J Clin
Invest. 2013; 123(7):2850-2861. doi: 10.1172/JCI67550) Avian Flu (H5N1), and the
Spanish  Flu,  as  CEL-SCI  scientists  are very  concerned  about the  possible
emergence of a new more virulent  hybrid virus through the  combination  of H1N1
and Avian Flu, or maybe  Spanish  Flu.  The Company  has  operations  in Vienna,
Virginia,  and in/near  Baltimore,  Maryland.



Multikine is the trademark that CEL-SCI has registered for this  investigational
therapy,  and this  proprietary name is subject to FDA review in connection with
its future anticipated regulatory submission for approval.

When used in this release,  the words "intends,"  "believes,"  "anticipated" and
"expects"  and similar  expressions  are  intended  to identify  forward-looking
statements.  Such statements are subject to risks and uncertainties  which could
cause actual results to differ  materially  from those  projected.  Factors that
could cause or contribute to such differences include, an inability to duplicate
the clinical results demonstrated in clinical studies, timely development of any
potential  products  that  can be  shown  to be safe  and  effective,  receiving
necessary  regulatory  approvals,  difficulties  in  manufacturing  any  of  the
Company's potential  products,  inability to raise the necessary capital and the
risk factors set forth from time to time in CEL-SCI  Corporation's  SEC filings,
including  but not  limited  to its  report  on Form  10-K  for the  year  ended
September 30, 2012. The Company undertakes no obligation to publicly release the
result of any revision to these forward-looking  statements which may be made to
reflect  the events or  circumstances  after the date  hereof or to reflect  the
occurrence of unanticipated events